satralizumab   

GtoPdb Ligand ID: 9093

Synonyms: SA-237 | SA237 | sapelizumab (perviously known as)
Compound class: Antibody
Comment: Satralizumab (previously referred to using the replaced INN sapelizumab) is an investigational humanized monoclonal antibody targeting the IL-6 receptor, with immunomodulatory potential. This antibody is an improved version of tocilizumab, with enhanced antigen-neutralizing ability and pharmacokinetics suitable for less frequent administration [1].
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. Peptide BLAST searches reveal identical matches between the heavy and light chain sequences as annotated in IMGT and SEQ IDs 26 and 29 respectively claimed in patent US8562991 [1]. This matches satralizumab to the Fv4-M73 construct in the patent.
References
1. Igawa T, Ishii S, Maeda A, Sakurai M, Kojima T, Tachibana T, Shiraiwa H, Tsunoda H, Higuchi Y. (2013)
Antibody molecules that bind to IL-6 receptor.
Patent number: US8562991 B2. Assignee: Chugai Seiyaku Kabushiki Kaisha. Priority date: 26/09/2008. Publication date: 22/10/2013.